NYBC congratulates Dr. Asim Debnath, Head of Laboratory of Molecular Modeling and Drug Design, Lindsay F. Kimball Research Institute (LFKRI) for the competitive renewal of his NIH R01 grant on anti-HIV drugs.


Dr. Debnath will continue his groundbreaking studies to design a novel class of anti-HIV drugs. Current concerns with existing anti-HIV drugs include (1) reliance on daily adherence, (2) long-term use resulting in long-term toxicity, (3) limited treatment options due to the development of drug resistance, (4) high cost, and finally, (5) the non-curative nature of current treatments.  Dr. Debnath takes into consideration of these limitations in his optimization strategy. Specifically, he plans to optimize the lead HIV-1 entry antagonists targeted to the CD4 binding site of HIV-1 envelope glycoprotein gp120 into clinically relevant and potent entry inhibitors lacking drug resistance properties. The goal is to develop novel, highly potent, and less toxic oral anti-HIV (anti-AIDS) drugs, which are expected to serve as a new arsenal for combination therapy, especially for treatment-experienced patients.”

The 5-year grant entitled, Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120 totals $3.1 million, of which NYBC receives $2.7 million. Collaborators on this grant include Dr. Andrea Altieri, Edasa Scientific Ltd, Russia; Dr. Peter Kwong, Chief, Structural Biology Section, Vaccine Research Center, NIAID, NIH; Dr. Eric Freed, Director, HIV Dynamics and Replication Program, National Cancer Institute, NIH; Prof. Alan Cooper, Emeritus Professor of Biophysical Chemistry, University of Glasgow.